Overview

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2020-11-30

Target enrollment:

Participant gender:

Summary

Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs). If researchers know about your biomarkers before you receive treatment, they may be able to prescribe a treatment that is better suited to your body's specific needs. The goal of this clinical research study is to learn if drug or drug combinations based on your biomarkers can help to control NSCLC. The safety of these drug combinations will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

AstraZeneca
Bayer
GlaxoSmithKline
Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
Novartis
OSI Pharmaceuticals
Yale University

Treatments:

Erlotinib Hydrochloride
Sorafenib